Breaking News Instant updates and real-time market news.

ADBE

Adobe

$276.80

1.21 (0.44%)

, JBL

Jabil

$27.33

0.53 (1.98%)

19:02
06/18/19
06/18
19:02
06/18/19
19:02

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Adobe (ADBE) up 3.9%... Jabil (JBL) up 2.5%... U.S. Steel (X) up 1.9% after Q2 guidance. ALSO HIGHER: ArQule (ARQL) up 3.4% after announcing BMO Prescriptions presentation on June 25th... Upwork (UPWK) up 1.3% after being initiated at Overweight at Cantor Fitzgerald. DOWN AFTER EARNINGS: Macom (MTSI) down 9.7% after cutting Q3 guidance... La-Z-Boy (LZB) down 7.7%. ALSO LOWER: Kura Oncology (KURA) down 8.4% after equity offering... Green Plains (GPRE) down 7.8% after suspending quarterly dividend... NCR Corp (NCR) down 5.0% after NY Post report that bidders have walked away... Zymeworks (ZYME) down 4.6% after equity offering... Genocea Biosciences (GNCA) down 3.7% after equity offering... YY (YY) down 2.5% after convertible note offering... Graftech (EAF) down 2.0% after mixed shelf offering. Movers as of 18:45ET.

ADBE

Adobe

$276.80

1.21 (0.44%)

JBL

Jabil

$27.33

0.53 (1.98%)

X

U.S. Steel

$14.58

0.62 (4.44%)

ARQL

ArQule

$9.37

-0.19 (-1.99%)

UPWK

Upwork

$15.15

-0.29 (-1.88%)

MTSI

Macom

$14.40

-0.02 (-0.14%)

LZB

La-Z-Boy

$29.76

-0.47 (-1.55%)

KURA

Kura Oncology

$18.73

-0.76 (-3.90%)

GPRE

Green Plains

$12.48

0.3 (2.46%)

NCR

NCR Corp.

$31.34

0.31 (1.00%)

ZYME

Zymeworks

$20.15

-0.51 (-2.47%)

GNCA

Genocea

$5.16

-0.24 (-4.44%)

YY

YY

$77.13

2.14 (2.85%)

EAF

GrafTech

$10.95

0.14 (1.30%)

  • 18

    Jun

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 25

    Jun

  • 20

    Jun

ADBE Adobe
$276.80

1.21 (0.44%)

04/29/19
MSCO
04/29/19
UPGRADE
Target $340
MSCO
Overweight
Morgan Stanley upgrades Adobe to Overweight on durable EPS growth
As previously reported, Morgan Stanley analyst Keith Weiss upgraded Adobe to Overweight from Equal Weight, stating that his field work, meetings with management and analysis of segment contribution margins have boosted his confidence in Adobe's ability to sustain EPS growth of over 20%, even if he assumes decelerating Digital Media growth. While he estimates that Digital Media could decelerate at a faster pace than consensus currently models, Weiss thinks that Digital Experience could accelerate organically and sustain revenue growth above current Street estimates, he tells investors. He raised his price target on Adobe shares to $340 from $282, adding that he sees "Growth at a Reasonable Price", or "GARP," software stocks that have durable EPS growth outperforming in 2019.
04/29/19
04/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew McClintock saying Target is taking market share from a "much weaker" retailer subset than other positive traffic retailers. 2. Sprouts Farmers Market (SFM) upgraded to Buy from Hold at Deutsche Bank. 3. American Airlines (AAL) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying American's lowering of its earnings guidance range last week was not unexpected given the recent rise in fuel prices and grounding of its MAX fleet. The analyst thinks the resetting of expectations by management establishes a "floor" for American's share price and provides the company a bit more "cushion" around its earnings targets. 4. Colgate-Palmolive (CL) upgraded to Neutral from Underweight at JPMorgan with analyst Andrea Teixeira saying the company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S. 5. Adobe (ADBE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying his field work, meetings with management and analysis of segment contribution margins have boosted his confidence in Adobe's ability to sustain EPS growth of over 20%, even if he assumes decelerating Digital Media growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/29/19
MSCO
04/29/19
UPGRADE
MSCO
Overweight
Adobe upgraded to Overweight from Equal Weight at Morgan Stanley
06/14/19
MSCO
06/14/19
NO CHANGE
Target $340
MSCO
Overweight
Adobe checks point to healthy demand, says Morgan Stanley
Morgan Stanley analyst Keith Weiss noted that Adobe has posted "modest beats" in the last two quarters, but he thinks a "solid beat and raise" in its upcoming second quarter report can get the stock "back on track." His checks with partners point to healthy customer demand and Weiss sees stronger seasonality sustaining Annual Recurring Revenue of greater than 20% in Q2, he tells investors in an earnings preview note. Weiss has an Overweight rating on Adobe shares with a $340 price target.
JBL Jabil
$27.33

0.53 (1.98%)

12/19/18
RBCM
12/19/18
NO CHANGE
Target $30
RBCM
Jabil price target raised to $30 from $29 at RBC Capital
RBC Capital analyst Amit Daryanani nudged his price target on Jabil to $30 rating after its "strong" Q1 results driven by a "combination of better than expected performance in both its DMS and EMS segments" and the upside in new business wins. The analyst also cites the company's raised FY19 revenue guidance forecast based on the management's expectations of "healthcare, packaging, automotive, 5G wireless and cloud contribute meaningfully" to its top line. Daryanani keeps his Sector Perform rating on Jabil, noting that its valuation is in line with its 10-year average trading multiple of 10-times forward 12-month earnings.
04/01/19
04/01/19
UPGRADE

Strong Buy
Jabil upgraded to Strong Buy ahead of an inflection in trends at Raymond James
As previously reported, Raymond James upgraded Jabil to Strong Buy from Market Perform and established a $34 price target. Analyst Adam Tindle thinks Jabil is entering another key metric inflection phase as both operating margin and free cash flow steadily improve on a year-over-year basis beginning in the May quarter. Tindle said new contractual wins have better characteristics on both margin and cash flow, combined with a continued tailwind from 5G implementation over the next few years, and an eventual rebound in semicap equipment trends.
04/01/19
RAJA
04/01/19
UPGRADE
RAJA
Strong Buy
Jabil upgraded to Strong Buy from Market Perform at Raymond James
12/11/18
WOLF
12/11/18
INITIATION
Target $25
WOLF
Peer Perform
Jabil initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Steven Milunovich started Jabil (JBL) with a Peer Perform rating and $25 price target, stating that although EMS names are moving up the value chain, he does not think "now is the time" for Jabil and Flex (FLEX).
X U.S. Steel
$14.58

0.62 (4.44%)

05/30/19
DBAB
05/30/19
DOWNGRADE
DBAB
Sell
U.S. Steel downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Nucor to Sell from Hold to reflect a more negative stance on steel.
05/30/19
DBAB
05/30/19
DOWNGRADE
Target $11
DBAB
Sell
U.S. Steel downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded U.S. Steel to Sell from Hold and lowered his price target for the shares to $11 from $20. The analyst made rating changes in the Steel and Service Centers space after reviewing his firm's pricing forecasts. Terry says that even though stocks have been already been under pressure, he's cautious on the near term for the Steel and Service Centers sub-sector. The analyst moved his recommendations to a more negative stance and sees value elsewhere, especially in precious metals.
06/04/19
GSCO
06/04/19
DOWNGRADE
Target $11
GSCO
Sell
U.S. Steel downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Matthew Korn downgraded U.S. Steel to Sell from Neutral and lowered his price target for the shares to $11 from $17. The analyst expects the stock to weaken as the market continues to absorb the effects of materially lower steel prices. This will likely pull down consensus EBITDA estimates and increase pressure on the company's balance sheet, Korn tells investors in a research note. The analyst says a number of investors he's spoken to are concerned about U.S. Steel's leverage and cash flows given the company's plan to spend $1.2B on upgrades to its Mon Valley Works facility, funded largely with new debt.
06/04/19
06/04/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. U.S. Steel (X) downgraded to Sell from Neutral at Goldman Sachs with analyst Matthew Korn saying he expects the stock to weaken as the market continues to absorb the effects of materially lower steel prices. 2. Box (BOX) downgraded to Hold from Buy at Canaccord with Canaccord analyst Richard Davis saying the company's fundamental position is "too strong" for it to be executing this sporadically. 3. Kohl's (KSS) downgraded to Underweight from Neutral at Atlantic Equities. 4. MercadoLibre (MELI) downgraded to Neutral from Buy at BTIG with analyst Marvin Fong saying the stock's 94% advance year-to-date has fixed the "glaring price inefficiency" that its stock price had previously represented. 5. Ensign Group (ENSG) downgraded to Hold from Buy at SunTrust with analyst David MacDonald saying he is positive on the company's "local structure and unique M&A strategy," along with its solid growth and value-unlocking pending spin. However, MacDonald notes that the upcoming changes in Ensign Group's reimbursement structure carry some "uncertainty" and also sees the risk/reward on the stock as "balanced" at 21-times his expected FY20 earnings multiple. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ARQL ArQule
$9.37

-0.19 (-1.99%)

06/17/19
ROTH
06/17/19
NO CHANGE
Target $20
ROTH
Buy
ArQule price target raised to $20 from $10 at Roth Capital
Roth Capital analyst Tony Butler raised his price target for ArQule to $20 from $10 after the company presented updated data from its first-in-human, single-arm Phase 1 study of ARQ 531, the first oral reversible BTK inhibitor for both wild-type and ibrutinib-resistant BTK-c481S mutation. The analyst reiterates a Buy rating on the shares.
06/14/19
ROTH
06/14/19
NO CHANGE
Target $13
ROTH
Buy
ArQule price target raised to $13 from $10 at Roth Capital
Roth Capital analyst Tony Butler said he is optimistic about the efficacy and safety profile of ARQ 531 following the company's presentation of trial data, investor call and his talk with management. However, he thinks the key uncertainty now is durability of responses, which he highlights as important given the refractory population and the fact that ibrutinib was also based on survival data. He has raised his view of the probability of success for ARQ 531 to 50% from 33% previously and increased his price target to $13 on ArQule shares, on which he keeps Buy rating.
05/29/19
RILY
05/29/19
NO CHANGE
Target $11
RILY
Buy
ArQule price target raised to $11 from $6.75 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for ArQule to $11 from $6.75 ahead of what he expects will be "positive" Phase I safety and efficacy results for ARQ531 at the European Hematology Association conference in June. The analyst reiterates a Buy rating on the shares.
04/11/19
RBCM
04/11/19
INITIATION
Target $9
RBCM
Outperform
ArQule initiated with an Outperform at RBC Capital
RBC Capital analyst Gregory Renza initiated ArQule with an Outperform rating and a price target of $9. The analyst is positive on the company's "unique clinical portfolio of precision-based kinase inhibitors in oncology and orphan disease." Renza also expects that portfolio to appreciate over the year with additional clinical data for ARQ '531 inhibitor and progress on miransertib further de-risking the investment story.
UPWK Upwork
$15.15

-0.29 (-1.88%)

04/11/19
BTIG
04/11/19
INITIATION
Target $45
BTIG
Buy
Upwork initiated with a Buy at BTIG
BTIG initiated Upwork with a Buy and $45 price target.
04/11/19
BTIG
04/11/19
INITIATION
Target $24
BTIG
Buy
Upwork initiated with a Buy at BTIG
BTIG analyst Marvin Fong started Upwork with a Buy rating and $24 price target. The company is the dominant online freelancing platform with eight times the market share of its closest peers, yet it has only 0.5% share of a $322B total addressable market, "auguring well for sustained growth," Fong tells investors in a research note. The analyst sees room for Upwork to "meaningfully increase its take rate over time." He would view any pullbacks in the stock as buying opportunities.
04/12/19
04/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Redfin (RDFN) initiated with an Outperform at Wedbush. 2. Autodesk (ADSK) initiated with a Buy at Mizuho. 3. Upwork (UPWK) initiated with a Buy at BTIG. 4. Otter Tail (OTTR) initiated with a Buy at Maxim. 5. Disney (DIS) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/18/19
CANT
06/18/19
INITIATION
Target $19
CANT
Overweight
Upwork initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Drew Kootman started Upwork with an Overweight rating and $19 price target.
MTSI Macom
$14.40

-0.02 (-0.14%)

05/08/19
CHLM
05/08/19
UPGRADE
Target $25
CHLM
Buy
Macom upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Richard Shannon upgraded Macom to Buy from Hold and raised his price target on the shares to $25 from $17.
05/08/19
05/08/19
UPGRADE
Target $25

Buy
Macom upgraded to Buy on long-term potential at Craig-Hallum
As previously reported, Craig-Hallum analyst Richard Shannon upgraded Macom to Buy from Hold and raised his price target on the shares to $25 from $17. The analyst now has confidence in the efficacy of the GaN/Si technology, which has only increased in the last quarter based on significant commitments from STMicro and Goertek. With Data Center likely bottomed out, the stock down 80% over the past two years, and a neutral sell-side rating profile, he thinks the near-term risks are limited. Overall, Shannon believes the upside potential is "too great," and the near-term company-specific risks quite limited.
05/16/19
STFL
05/16/19
UPGRADE
STFL
Hold
Macom upgraded to Hold from Sell at Stifel
05/16/19
STFL
05/16/19
UPGRADE
Target $14
STFL
Hold
Stifel says new CEO has 'impressive' track record, upgrades Macom to Hold
As previously reported, Stifel analyst Tore Svanberg upgraded Macom to Hold from Sell after the company announced Stephen Daly as its new President and CEO. Though Svanberg still sees the company facing significant risks - including a challenging environment, China trade tensions, significant debt, and limited free cash flow - he believes Daly brings with him "an impressive track record" of leadership and execution. While awaiting greater clarity into management's longer-term strategy, the analyst raised his price target on Macom shares to $14 from $12.
LZB La-Z-Boy
$29.76

-0.47 (-1.55%)

08/23/18
08/23/18
DOWNGRADE

Sector Weight
La-Z-Boy downgraded to Sector Weight on valuation at KeyBanc
As previously reported, KeyBanc analyst Bradley Thomas downgraded La-Z-Boy to Sector Weight from Overweight on valuation. With the stock 20%-plus year over year and valuation elevated, the analyst believes the risk/reward for shares is more balanced on a six-month time frame. Thomas sees organic sales moderating from Q1, and incremental margin pressure in the quarters ahead. Lastly, while difficult to quantify, China tariffs could lead to downside to his current EPS estimates if exemptions are not made for the industry.
08/23/18
08/23/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Duluth Holdings (DLTH) downgraded to Neutral from Outperform at Baird. 2. La-Z-Boy (LZB) downgraded to Sector Weight from Overweight at KeyBanc with analyst Bradley Thomas citing valuation. 3. PermRock Royalty Trust (PRT) downgraded to Hold from Buy at Stifel with analyst Timothy Howard saying he believes significant long-term value remains in the trust, but cites "elevated" capital spending in the near term and "Permian differential uncertainty" for the downgrade. 4. ABM (ABM) downgraded to Neutral from Outperform at Baird with analyst Andrew Wittmann saying he sees the risk/reward as more balanced given near-term uncertainties and a possible risk to near-term guidance. 5. Coca-Cola Amatil (CCLAY) downgraded to Sell from Neutral at UBS and to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/17/18
SIDC
12/17/18
UPGRADE
Target $34
SIDC
Buy
La-Z-Boy upgraded to Buy from Neutral at Sidoti
Sidoti analyst Anthony Lebiedzinski upgraded La-Z-Boy to Buy from Neutral following a 34% decline in the shares since August. He believes the company is well-positioned to deal with tariffs compared to most peers and sees it product mix skewed to upholstery helping it continue to profitably increase revenue. Lebiedzinski keeps a $34 price target on La-Z-Boy shares.
06/06/19
SIDC
06/06/19
DOWNGRADE
Target $35
SIDC
Neutral
La-Z-Boy downgraded to Neutral from Buy at Sidoti
Sidoti analyst Anthony Lebiedzinski downgraded La-Z-Boy to Neutral from Buy and lowered his price target on the shares to $35 from $38 after the company pre-announced FY19 sales and earnings that were below consensus estimates. The Trump administration's threats for tariffs on goods imported from Mexico adds another layer of risk given La-Z-Boy's reliance on cut-and-sew kits from a Mexico facility and Joybird's manufacturing plant in Tijuana, Lebiedzinski said.
KURA Kura Oncology
$18.73

-0.76 (-3.90%)

04/03/19
PIPR
04/03/19
NO CHANGE
PIPR
Overweight
Piper says Kura's potential patient population for tipifarnib keeps growing
After Kura Oncology presented additional data on tipifarnib, a farnesyltransferase inhibitor/HRAS inhibitor that downregulates expression of CXCL12, Piper Jaffray analyst Tyler Van Buren said the number of potential indications for the drug "continues to multiply" as initial clinical data suggest diffuse large B-cell lymphoma and cutaneous T-cell lymphoma patients could benefit from treatment in addition to the already identified cancer indications. The "broad mechanism of tipifarnib is becoming clear" and the potential patient population keeps growing, "well beyond what investors are currently appreciating," according to Van Buren. He keeps an Overweight rating on Kura shares.
05/24/19
SBSH
05/24/19
NO CHANGE
Target $25
SBSH
Buy
Kura Oncology price target raised to $25 from $18 at Citi
Citi analyst Joel Beatty raised his price target for Kura Oncology to $25 from $18 saying he believes the data to date support that tipifarnib is likely effective for HRAS-mutant head and neck squamous cell carcinoma. More Phase 2 data in this setting in the second half of 2019 could add further support, Beatty tells investors in a research note. He keeps a Buy rating on Kura Oncology shares.
06/14/19
HCWC
06/14/19
NO CHANGE
Target $31
HCWC
Buy
Kura reported 'crucial' biomarker set of data, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating and $31 price target on Kura Oncology after the company announced positive follow-up data from the ongoing Phase 2 clinical trial addressing the anti-tumor role of tipifarnib in PTCL patients and met the primary endpoint. In a research note to investors, the analyst says Kura reported a crucial biomarker set of data, the enrichment of high rate of mutation/variation of the killer cell immunoglobulin-like receptors, including KIR3DL2 in AITL patients and its role in tipifarnib outcome. Kura's targeted approaches could generate fast and meaningful information on crucial tumor indications and patient cohorts where tipifarnib may see more robust clinical outcomes, increasing his confidence on tipifarnib's likelihood of success, the analyst contends.
06/17/19
WEDB
06/17/19
NO CHANGE
Target $30
WEDB
Outperform
Kura Oncology price target raised to $30 from $23 at Wedbush
Wedbush analyst Robert Driscoll raised his price target for Kura Oncology to $30 from $23 after the company announced positive data from an ongoing Phase 2 study evaluating tipifarnib in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma patients carrying a CXCL12 3' UTR SNP. Overall, the analyst views the "impressive" data set as highly supportive of a registrational pathway in AITL/PTCL CXCL12+ patients, and further validating of the broadening clinical development of tipifarnib into additional indications to potentially include pancreatic, DLBCL, and AML. Driscoll reiterates an Outperform rating on the shares.
GPRE Green Plains
$12.48

0.3 (2.46%)

10/11/18
SPHN
10/11/18
NO CHANGE
Target $18
SPHN
Equal Weight
Green Plains likely to announce more plant sales this month, says Stephens
After Green Plains (GPRE) announced an agreement to sell three ethanol plants to Valero (VLO) and an agreement to acquire storage and transportation assets from Green Plains Partners (GPP), Stephens analyst Farha Aslam said she sees this as the first step in the company's plan to divest non-core assets to reduce debt. She expects an announcement of two to three more plant sales to come later this month, Aslam added. The deal with Valero, which involves about 20% of Green Plains' reported capacity, is anticipated along with the Partners transaction to be 10c dilutive to FY19 EPS, Aslam estimates. She lowered her price target on Green Plains shares to $18 from $20 and keeps an Equal Weight rating on the stock, citing what she views as "challenging" fundamentals in the ethanol industry.
12/21/18
STFL
12/21/18
DOWNGRADE
Target $14
STFL
Hold
Green Plains Partners downgraded to Hold from Buy at Stifel
Stifel analyst Selman Akyol downgraded Green Plains Partners (GPP) to Hold and lowered his price target for the shares to $14 from $16. The analyst cites the ongoing asset optimization program at the company's parent, Green Plains (GPRE), as well as the "overall current market sentiment." With more potential asset sales looming, the analyst prefers to be on the sidelines at this time.
02/11/19
ROTH
02/11/19
NO CHANGE
Target $16
ROTH
Buy
Green Plains price target lowered to $16 from $25 at Roth Capital
Roth Capital analyst Craig Irwin lowered his price target for Green Plains to $16 from $25 ahead of quarterly results. The balance sheet will be a focus, where the analyst expects cash available for share repurchases to be a top investor focus. With the asset sales complete and Term Loan B repaid, the company should retain a much improved risk profile for 2019, while waiting for crosswinds that can improve industry crush margins, he contends. The analyst reiterates a Buy rating on the shares.
02/12/19
CHLM
02/12/19
NO CHANGE
Target $19
CHLM
Buy
Green Plains price target lowered to $19 from $24 at Craig-Hallum
Craig-Hallum analyst Eric Stine lowered his price target for Green Plains to $19 from $24 following an important, but also "very messy," quarter for the company. The analyst reiterates a Buy rating on the shares.
NCR NCR Corp.
$31.34

0.31 (1.00%)

03/25/19
JPMS
03/25/19
DOWNGRADE
Target $32
JPMS
Neutral
NCR Corp. downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded NCR Corp. to Neutral from Overweight with an unchanged price target of $32. The stock looks attractively valued but its mix-shift toward software and software-as-a-service will not be fast enough to "trigger a re-rating of the stock in the next 6-12 months," Coster tells investors in a research note. The analyst thinks NCR shares will likely be range-bound pending evidence that its new management can drive faster growth in software and SaaS.
01/08/19
DADA
01/08/19
UPGRADE
Target $30
DADA
Buy
NCR Corp upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Matt Summerville upgraded NCR Corp to Buy from Neutral and raised his price target to $30 from $27.50. The analyst points to rising consistency of the company's execution under the new leadership since the departure of CEO Bill Nuti and CFO Bob Fishman, anticipating NCR to return to positive organic growth in 2019.
12/18/18
RBCM
12/18/18
UPGRADE
Target $40
RBCM
Top Pick
NCR Corp. upgraded to Top Pick at RBC Capital on transition in sales mix
As reported earlier, RBC Capital analyst Daniel Perlin upgraded NCR Corp to Top Pick from Outperform and raised his price target to $40 from $36. The analyst believes that the stock offers "the best risk-reward trade off" in any of his covered names heading into 2019 as the new management's sales mix shift to higher recurring revenues will offer "more financial consistency" and produce a multiple re-rating. Beyond the supply chain issue fixes, Perlin expects the management to "get new products into the market" and "leverage the global sales distribution model" in the near term, followed by the company's continued M&A leverage toward "additional products and services" in the longer term.
12/18/18
RBCM
12/18/18
UPGRADE
RBCM
Top Pick
NCR Corp. upgraded to Top Pick from Outperform at RBC Capital
ZYME Zymeworks
$20.15

-0.51 (-2.47%)

11/28/18
ADAM
11/28/18
NO CHANGE
Target $21
ADAM
Buy
Zymeworks partnership deal with BeiGene a positive, says Canaccord
Canaccord analyst Arlinda Lee views Zymeworks' (ZYME) partnership with BeiGene (BGNE) as a positive as it ties in the company with a commercial-stage pharma company that has experience and a foothold in the Asia-Pacific region, where gastric cancers are more prevalent. She continues to view Zymeworks' complementary suite of "plug and play" platform technologies, particularly in its bi specific antibody platform, as attractive. Lee reiterated her Buy rating and $21 price target on Zymeworks shares.
04/22/19
WELS
04/22/19
NO CHANGE
WELS
Zymeworks price target raised to $42 from $37 at Wells Fargo
Wells Fargo analyst Jim Birchenough reiterated an Outperform rating on Zymeworks and raised his price target on shares to $42 from $37 following the recent initiation of phase 2 development for HER2 biparatopic antibody therapeutic ZW25 as frontline treatment for metastatic HER2+ gastroesophageal cancers. The analyst said he sees a reasonable likelihood of success due to strong phase 1b data.
08/02/18
SBSH
08/02/18
UPGRADE
Target $20
SBSH
Buy
Zymeworks upgraded to Buy from Neutral at Citi
Citi analyst Yigal Nochomovitz upgraded Zymeworks to Buy and raised his price target for the shares to $20 from $19.
08/02/18
SBSH
08/02/18
UPGRADE
Target $20
SBSH
Buy
Citi upgrades Zymeworks to Buy on valuation
Citi analyst Yigal Nochomovitz upgraded Zymeworks to Buy from Neutral and raised his price target for the shares to $20 from $19. The company is well capitalized following the June offering with a cash runway expected to last through at least one planned Phase 2/3 registrational study for ZW-25, Nochomovitz tells investors in a research note. The analyst cites valuation for his upgrade to Buy.
GNCA Genocea
$5.16

-0.24 (-4.44%)

02/28/19
HCWC
02/28/19
NO CHANGE
Target $5.75
HCWC
Buy
Genocea price target raised on higher GEN-009 odds of success at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated his Buy rating on Genocea Biosciences and raised his price target to $5.75 from $5.00 after increasing his projected chance of success for GEN-009 to 15% from 10% based on the "increasingly strong profile" of the ATLAS platform, as demonstrated most recently at SITC 2018. He also adjusted the share count to account for a recent equity raise and projected impacted from a second tranche of this raise. Pantginis keeps a Buy rating on Genocea.
06/03/19
HCWC
06/03/19
NO CHANGE
Target $42
HCWC
Buy
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Genocea Biosciences to $42 from $5.75 after the company present immunological data from the ongoing Phase 1/2a study with GEN-009. With these data, "ATLAS is now squarely thrust into the neoantigen fray with potentially superior data compared to comps that use algorithm approaches," Pantginis tells investors in a research note. He keeps a Buy rating on shares of Genocea.
YY YY
$77.13

2.14 (2.85%)

05/29/19
NOMU
05/29/19
UPGRADE
Target $77
NOMU
Buy
Nomura Instinet upgrades YY to Buy after 27% correction
Nomura Instinet analyst Jialong Shi upgraded YY (YY) to Buy from Neutral while lowering his price target for the shares to $77 from $81. The risk/reward is more favorable with the stock down 27% from its recent peak, Shi tells investors in a research note. The analyst thinks the current market volatility, triggered by macro concerns, may benefit "cheap stocks with macro-defensive businesses" such as YY and Momo (MOMO).
05/29/19
BNCH
05/29/19
NO CHANGE
Target $95
BNCH
Buy
YY price target lowered to $95 from $106 at Benchmark
Benchmark analyst Fawne Jiang maintained a Buy rating on YYY but lowered her price target to $95 from $106 following the company's Q1 results, which beat the consensus for revenue but missed on EPADS. In a research note to investors, Jiang says she expects YY's near-term margins outlook to be dragged down by stepped up investment in global expansion and AI technology and views YY as a value play for longer term oriented investors.
05/29/19
05/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Flex (FLEX) upgraded to Overweight from Neutral at JPMorgan with analyst Paul Coster citing valuation. 2. Allstate (ALL) and Hartford Financial (HIG) were upgraded to Buy from Neutral at Goldman Sachs. 3. Rockwell Automation (ROK) upgraded to Buy from Hold at Gabelli with analyst Justin Bergner saying the negative investor sentiment stemming from "skepticism" of its software partnership strategy and the decline in the relevance of its programmable logic controller is unwarranted. 4. Falcon Minerals (FLMN) upgraded to Buy from Hold at Stifel with analyst Timothy Howard saying Falcon shares have underperformed over the last 30 days, falling 17% compared to peers down 6% and crude oil prices down 7%. 5. YY (YY) upgraded to Buy from Neutral at Nomura Instinet with t analyst Jialong Shi saying the risk/reward is more favorable with the stock down 27% from its recent peak. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/29/19
NOMU
05/29/19
UPGRADE
NOMU
Buy
YY upgraded to Buy from Neutral at Nomura Instinet
EAF GrafTech
$10.95

0.14 (1.30%)

02/11/19
JPMS
02/11/19
NO CHANGE
Target $24
JPMS
Overweight
GrafTech pricing in too steep a drop in electrode prices, says JPMorgan
JPMorgan analyst Michael Gambardella lowered his price target for GrafTech to $24 from $29.50 and keeps an Overweight rating on the name. The analyst reduced his estimates to reflect lower volumes without the restart of St. Mary's and to incorporate higher spot needle coke prices. However, he forecasts earnings per share of $2.87 in 2019 and $2.83 in 2020, while he estimates that GrafTech's current stock price is discounting earnings closer to $1.55. This level of earnings is very unlikely in the near-term, Gambardella tells investors in a research note. GrafTech's contracted graphite electrode price averages between $9,600/tonne and $9,800/tonne through 2022, with contracted volumes accounting for between 60% and 74% of its production over the same time frame, adds the analyst. He thinks the stock is pricing in too steep a drop in graphite electrode prices.
04/01/19
SBSH
04/01/19
NO CHANGE
Target $17
SBSH
Buy
GrafTech price target lowered to $17 from $21 at Citi
Citi analyst Alexander Hacking lowered his price target for GrafTech to $17 from $21 but keeps a Buy rating on the shares. The analyst says his target price is very sensitive to long-term electrode prices, which he models at $5,500 per ton. GrafTech is generating "very strong" near-term free cash flow based on current above-normalized electrode prices, Hacking tells investors in a research note. He expects shareholder returns of 10%-15% in 2019, with the remainder allocated to debt reduction. The main overhangs on the stock are the shareholding structure and investor concerns around owning peak electrode prices, says Hacking.
04/22/19
SBSH
04/22/19
DOWNGRADE
Target $12
SBSH
Sell
GrafTech downgraded to Sell from Buy at Citi
Citi analyst Alexander Hacking double downgraded GrafTech to Sell from Buy and lowered his price target for the shares to $12 from $17. The analyst sees China graphite electrode prices declining faster than previously thought due to capacity expansion.
01/25/19
JPMS
01/25/19
NO CHANGE
Target $29.5
JPMS
Overweight
GrafTech contract business alone worth $14 per share, says JPMorgan
Shares of GrafTech have been pressured by both falling Chinese spot prices for graphite electrodes as well as concerns that it may not restart its St. Mary's facility, JPMorgan analyst Michael Gambardella tells investors in a research note. While the analyst expects consensus estimates to come down, he believes that at $12.54 per share, GrafTech's long-term contracts book of business should be valued above the current stock price. He calculates an implied stock price of $14 on just GrafTech's contract business and believes contributions from its spot business could add an additional $4-$6 per share. Gambardella keeps an Overweight rating on GrafTech with a $29.50 price target.

TODAY'S FREE FLY STORIES

COT

Cott Corp.

$12.34

0.05 (0.41%)

20:29
07/23/19
07/23
20:29
07/23/19
20:29
Upgrade
Cott Corp. rating change at Goldman Sachs »

Cott Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 25

    Sep

20:25
07/23/19
07/23
20:25
07/23/19
20:25
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

T

AT&T

$32.09

-0.05 (-0.16%)

, BA

Boeing

$372.91

-0.48 (-0.13%)

20:25
07/23/19
07/23
20:25
07/23/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

T

AT&T

$32.09

-0.05 (-0.16%)

BA

Boeing

$372.91

-0.48 (-0.13%)

TMO

Thermo Fisher

$293.82

2.07 (0.71%)

NEE

NextEra Energy

$207.31

-2.05 (-0.98%)

UPS

UPS

$105.24

1.25 (1.20%)

ANTM

Anthem

$302.82

1.04 (0.34%)

CAT

Caterpillar

$138.07

2.87 (2.12%)

BSX

Boston Scientific

$42.80

0.3 (0.71%)

NOC

Northrop Grumman

$324.01

0.93 (0.29%)

GD

General Dynamics

$185.92

1.295 (0.70%)

VFC

VF Corp.

$88.25

1.41 (1.62%)

APH

Amphenol

$98.36

1.185 (1.22%)

HLT

Hilton

$95.18

1.95 (2.09%)

FCX

Freeport McMoRan

$11.65

0.16 (1.39%)

SC

Santander Consumer

$25.74

0.49 (1.94%)

KNX

Knight-Swift

$37.87

0.9 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 30

    Oct

  • 13

    Nov

  • 02

    Dec

COT

Cott Corp.

$12.34

0.05 (0.41%)

20:15
07/23/19
07/23
20:15
07/23/19
20:15
Upgrade
Cott Corp. rating change at Goldman Sachs »

Cott Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 25

    Sep

RARX

RA Pharmaceuticals

$33.58

-2.43 (-6.75%)

20:11
07/23/19
07/23
20:11
07/23/19
20:11
Syndicate
RA Pharmaceuticals 4M share Secondary priced at $32.50 »

Jefferies, BMO Capital,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CUTR

Cutera

$24.40

0.19 (0.78%)

20:04
07/23/19
07/23
20:04
07/23/19
20:04
Hot Stocks
Cutera gets approval of Brazil's ANVISA for truSculpt »

Cutera announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 13

    Nov

ITCI

Intra-Cellular

$8.18

-3.81 (-31.78%)

19:44
07/23/19
07/23
19:44
07/23/19
19:44
Hot Stocks
Intra-Cellular updates on lumateperone info provided to FDA »

Intra-Cellular Therapies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 27

    Sep

SCHW

Charles Schwab

$43.54

0.38 (0.88%)

19:28
07/23/19
07/23
19:28
07/23/19
19:28
Periodicals
Charles Schwab CMO, EVP of investor services to leave, BI says »

Charles Schwab is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

FB

Facebook

$202.38

0.06 (0.03%)

19:26
07/23/19
07/23
19:26
07/23/19
19:26
Periodicals
Facebook CEO must certify compliance under FTC privacy agreement, WSJ says »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

AXP

American Express

$128.20

2.19 (1.74%)

19:24
07/23/19
07/23
19:24
07/23/19
19:24
Periodicals
AmEx to refund $1.6M after finding salespeople misrepresented pricing, WSJ says »

American Express is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

OBE

Obsidian Energy

$1.00

0.0087 (0.88%)

19:22
07/23/19
07/23
19:22
07/23/19
19:22
Hot Stocks
Obsidian Energy regains compliance with NYSE listing standards »

Obsidian Energy received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEFT

Euronet

$165.34

1.22 (0.74%)

19:16
07/23/19
07/23
19:16
07/23/19
19:16
Earnings
Breaking Earnings news story on Euronet »

Euronet Worldwide sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Aug

  • 25

    Sep

  • 14

    Nov

EEFT

Euronet

$165.34

1.22 (0.74%)

19:16
07/23/19
07/23
19:16
07/23/19
19:16
Earnings
Euronet Worldwide reports Q2 adjusted EPS $1.69, consensus $1.69 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Aug

  • 25

    Sep

  • 14

    Nov

CALX

Calix

$7.30

0.155 (2.17%)

19:13
07/23/19
07/23
19:13
07/23/19
19:13
Earnings
Calix sees Q3 adjusted EPS 2c-6c, consensus 10c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CALX

Calix

$7.30

0.155 (2.17%)

19:12
07/23/19
07/23
19:12
07/23/19
19:12
Earnings
Calix reports Q2 adjusted EPS (1c), consensus (3c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

WE

We Company

$0.00

(0.00%)

19:06
07/23/19
07/23
19:06
07/23/19
19:06
Periodicals
WeWork eyes September IPO, WSJ reports »

WeWork Companies is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIC

Eagle Point Income Company

$0.00

(0.00%)

19:03
07/23/19
07/23
19:03
07/23/19
19:03
Syndicate
Eagle Point Income Company 1.2M share IPO priced at $19.89 »

National Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTS

Tile Shop

$3.08

-0.88 (-22.22%)

18:57
07/23/19
07/23
18:57
07/23/19
18:57
Downgrade
Tile Shop rating change at Telsey Advisory »

Tile Shop downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

AAPL

Apple

$208.85

1.64 (0.79%)

, GOOG

Alphabet

$1,146.62

8.53 (0.75%)

18:57
07/23/19
07/23
18:57
07/23/19
18:57
Periodicals
Apple, Google, Facebook, others petition FCC over VLP Wi-Fi category, Verge says »

Apple (AAPL), Google…

AAPL

Apple

$208.85

1.64 (0.79%)

GOOG

Alphabet

$1,146.62

8.53 (0.75%)

GOOGL

Alphabet Class A

$1,148.77

9.25 (0.81%)

MSFT

Microsoft

$139.29

0.88 (0.64%)

FB

Facebook

$202.38

0.06 (0.03%)

HPQ

HP Inc.

$21.64

0.2 (0.93%)

QCOM

Qualcomm

$74.10

-1.83 (-2.41%)

INTC

Intel

$51.76

0.4 (0.78%)

AVGO

Broadcom

$300.79

4.68 (1.58%)

MRVL

Marvell

$26.50

0.64 (2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 27

    Oct

JNCE

Jounce Therapeutics

$4.10

-0.1 (-2.38%)

, TER

Teradyne

$48.09

1.26 (2.69%)

18:56
07/23/19
07/23
18:56
07/23/19
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Jounce…

JNCE

Jounce Therapeutics

$4.10

-0.1 (-2.38%)

TER

Teradyne

$48.09

1.26 (2.69%)

EW

Edwards Lifesciences

$195.47

1.55 (0.80%)

MANH

Manhattan Associates

$72.91

1.16 (1.62%)

SNAP

Snap

$14.85

0.71 (5.02%)

TXN

Texas Instruments

$120.05

1.89 (1.60%)

OLBK

Old Line Bancshares

$26.14

(0.00%)

CSL

Carlisle

$132.30

2.445 (1.88%)

CMG

Chipotle

$740.42

-1.88 (-0.25%)

CNI

Canadian National

$91.05

-0.07 (-0.08%)

DFS

Discover

$84.54

2.205 (2.68%)

NAVI

Navient

$13.71

0.27 (2.01%)

WFC

Wells Fargo

$47.20

0.7 (1.51%)

IRBT

iRobot

$89.64

-2.7 (-2.92%)

RHI

Robert Half

$58.81

1.45 (2.53%)

V

Visa

$180.89

0.34 (0.19%)

SGEN

Seattle Genetics

$75.88

-0.22 (-0.29%)

FB

Facebook

$202.38

0.06 (0.03%)

TWTR

Twitter

$37.90

0.32 (0.85%)

AMZN

Amazon.com

$1,994.44

8.51 (0.43%)

GOOG

Alphabet

$1,146.62

8.53 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 03

    Aug

  • 08

    Aug

  • 21

    Aug

  • 04

    Sep

  • 05

    Sep

  • 09

    Sep

  • 11

    Sep

  • 23

    Sep

  • 25

    Sep

  • 12

    Oct

  • 15

    Oct

  • 27

    Oct

  • 13

    Nov

  • 24

    Jul

DB

Deutsche Bank

$7.95

0.16 (2.05%)

18:45
07/23/19
07/23
18:45
07/23/19
18:45
Periodicals
Deutsche Bank's credit derivatives seen as hard to offload, Reuters says »

Three bank insiders have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

NHI

National Health Investors

$79.63

0.91 (1.16%)

18:35
07/23/19
07/23
18:35
07/23/19
18:35
Hot Stocks
National Health Investors to invest $7.6M in Colorado community »

National Health Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

RGLS

Regulus

$1.13

-0.07 (-5.83%)

18:32
07/23/19
07/23
18:32
07/23/19
18:32
Hot Stocks
Regulus announces a program update for RGLS4326 »

Regulus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

MPW

Medical Properties Trust

$17.67

0.12 (0.68%)

18:26
07/23/19
07/23
18:26
07/23/19
18:26
Upgrade
Medical Properties Trust rating change at Stifel »

Medical Properties Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$119.22

10.68 (9.84%)

18:24
07/23/19
07/23
18:24
07/23/19
18:24
Hot Stocks
Hasbro CEO: We have a great management team »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.